AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15553108 — intervention group
Group type: COMPARATOR
Intervention: Test tablet vs Reference tablet
Number of subjects: 25
Study 15553108 — intervention group
Group type: COMPARATOR
Intervention: Test tablet vs Oral solution
Number of subjects: 25
Study 15553108 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine
Number of subjects: 25
Study 12240665 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 50
Study 12240665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9007343 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine and 1:100,000 norepinephrine (Mepivanor)
Number of subjects: 71
Study 9007343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetracaine, 1:4,000 adrenaline, and 4% cocaine (TAC)
Number of subjects: 71
Study 9007343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine infiltration
Number of subjects: 71
Study 9007343 — intervention group
Group type: COMPARATOR
Intervention: TAC
Number of subjects: 71
Study 9007343 — intervention group
Group type: COMPARATOR
Intervention: Mepivanor
Number of subjects: 71
Study 8305640 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg every 12 h)
Number of subjects: 15
Study 8305640 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg every 12 h) + Aspirin (75 mg/day)
Number of subjects: 15
Study 3329964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 4 mg or 8 mg orally three times daily for two successive three-week periods
Number of subjects: 56
Study 3329964 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally three times daily for two successive three-week periods
Number of subjects: 56
Study 3329964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 56
Study 31486332 — intervention group
Group type: EXPERIMENTAL
Intervention: HOM-HEMP intervention
Number of subjects: 10
Study 30725015 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered rehabilitation program
Number of subjects: 271
Study 30725015 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 271
Study 27717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 50μg
Number of subjects: 144
Study 27717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100μg
Number of subjects: 144
Study 27717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 150μg
Number of subjects: 144
Study 27717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30mg before leaving the operating room and 15mg every 6h for 24h
Number of subjects: 144
Study 27717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (patient-controlled)
Number of subjects: 144
Study 27717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100μg and 150μg
Number of subjects: 144
Study 27717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 50μg, 100μg, 150μg
Number of subjects: 144
Study 24131665 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% xenon anaesthesia
Number of subjects: 0
Study 24131665 — intervention group
Group type: COMPARATOR
Intervention: 2.0% sevoflurane anaesthesia
Number of subjects: 0
Study 22820341 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left PPC
Number of subjects: 30
Study 22820341 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS over left PPC
Number of subjects: 30
Study 22820341 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS over left PPC
Number of subjects: 30
Study 22820341 — intervention group
Group type: COMPARATOR
Intervention: tDCS over right PPC (anodal, sham, cathodal)
Number of subjects: 30
Study 20429647 — intervention group
Group type: EXPERIMENTAL
Intervention: SRPL (SRP and laser)
Number of subjects: 19
Study 20429647 — intervention group
Group type: EXPERIMENTAL
Intervention: L (laser)
Number of subjects: 19
Study 20429647 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP (SRP only)
Number of subjects: 19
Study 20429647 — intervention group
Group type: COMPARATOR
Intervention: C (no treatment)
Number of subjects: 19
Study 18480686 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg PO twice a day)
Number of subjects: 13
Study 18480686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16260821 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality orientation therapy combined with donepezil
Number of subjects: 79
Study 16260821 — intervention group
Group type: COMPARATOR
Intervention: Control group (donepezil only)
Number of subjects: 79
Study 11868799 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 12
Study 11868799 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI + SP
Number of subjects: 12
Study 11868799 — intervention group
Group type: EXPERIMENTAL
Intervention: NEB
Number of subjects: 12
Study 12905915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse used twice daily for 21 days
Number of subjects: 40
Study 12905915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse used with routine daily brushing for 180 days
Number of subjects: 40
Study 12905915 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 40
Study 7495392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (IBO) 100 mg
Number of subjects: 12
Study 7495392 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg
Number of subjects: 12
Study 7495392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 2114069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical adriamycin
Number of subjects: 40
Study 2114069 — intervention group
Group type: COMPARATOR
Intervention: Oral ftorafur
Number of subjects: 40
Study 677195 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fetal heart rate monitoring
Number of subjects: 504
Study 677195 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 504
Study 30144228 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 126
Study 30144228 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study 30144228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WET and CPT
Number of subjects: 126
Study 27289009 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-neutral program
Number of subjects: 80
Study 27289009 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss program
Number of subjects: 80
Study 27289009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 80
Study 24059906 — intervention group
Group type: COMPARATOR
Intervention: NaFeEDTA-fortified oat beverage without vitamin C
Number of subjects: 19
Study 24059906 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified oat beverage with vitamin C
Number of subjects: 19
Study 22764218 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised emails inviting interaction about chlamydia testing
Number of subjects: 704
Study 22764218 — intervention group
Group type: COMPARATOR
Intervention: Regular impersonal emails
Number of subjects: 704
Study 22764218 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged in email interaction
Number of subjects: 704
Study 22764218 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (condom use, changes in knowledge and attitudes)
Number of subjects: 704
Study 20644719 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual discrimination training
Number of subjects: 0
Study 18567279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (60 mg/day)
Number of subjects: 116
Study 18567279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 16468483 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 containing toothpaste and mouthrinse (combined group)
Number of subjects: 42
Study 16468483 — intervention group
Group type: COMPARATOR
Intervention: AmF/SnF2 containing toothpaste only (toothpaste only group)
Number of subjects: 42
Study 12459934 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 1 g/day
Number of subjects: 160
Study 12459934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10650257 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 80
Study 10650257 — intervention group
Group type: COMPARATOR
Intervention: Band ligation plus sclerotherapy
Number of subjects: 80
Study 8892168 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic giardiasis group
Number of subjects: 2
Study 8892168 — intervention group
Group type: COMPARATOR
Intervention: Control group (anemia without intestinal parasitosis)
Number of subjects: 2
Study 1495291 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (target hematocrit 32%)
Number of subjects: 39
Study 1495291 — intervention group
Group type: COMPARATOR
Intervention: Conservative transfusion strategy (target hematocrit <25%)
Number of subjects: 39
Study 1495291 — intervention group
Group type: COMPARATOR
Intervention: Conservative transfusion strategy
Number of subjects: 39
Study 1495291 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative transfusion strategy with transfusion between exercise tests
Number of subjects: 39
Study 6862578 — intervention group
Group type: EXPERIMENTAL
Intervention: DAMME (metenkephalin analog)
Number of subjects: 16
Study 6862578 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 16
Study 6862578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 6862578 — intervention group
Group type: EXPERIMENTAL
Intervention: DAMME
Number of subjects: 16
Study 31397022 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy nurse competency framework intervention
Number of subjects: 312
Study 31397022 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 312
Study 27593709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation group (500 pulses of 10 Hz rTMS over ipsilesional and contralesional motor cortices)
Number of subjects: 35
Study 27593709 — intervention group
Group type: COMPARATOR
Intervention: Unilateral stimulation group (500 pulses of 10 Hz rTMS over ipsilesional motor cortex and sham rTMS over contralesional hemisphere)
Number of subjects: 35
Study 27593709 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation group (sham rTMS at bilateral motor cortices)
Number of subjects: 35
Study 27282084 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilized group (8h left hand immobilization)
Number of subjects: 21
Study 27282084 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal limb use)
Number of subjects: 21
Study 24515912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise therapy combined with total glucosides form Shaoyao Gancao decoction
Number of subjects: 0
Study 24515912 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation exercise therapy only (control group)
Number of subjects: 0
Study 22926597 — intervention group
Group type: EXPERIMENTAL
Intervention: D-MPH-ER 30 mg/day
Number of subjects: 165
Study 22926597 — intervention group
Group type: EXPERIMENTAL
Intervention: D-MPH-ER 20 mg/day
Number of subjects: 165
Study 22926597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 20479948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Atorvastatin (AML/ATO) + Therapeutic Lifestyle Changes (TLC)
Number of subjects: 0
Study 20479948 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (AML) + Therapeutic Lifestyle Changes (TLC)
Number of subjects: 0
Study 20479948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Atorvastatin (AML/ATO) + TLC
Number of subjects: 0
Study 18829902 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lumbar corset for eight weeks full-time (experimental group)
Number of subjects: 90
Study 18829902 — intervention group
Group type: COMPARATOR
Intervention: No postoperative corset (control group)
Number of subjects: 90
Study 18829902 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lumbar corset (experimental group)
Number of subjects: 90
Study 15925862 — intervention group
Group type: EXPERIMENTAL
Intervention: stacked ABR
Number of subjects: 54
Study 15925862 — intervention group
Group type: COMPARATOR
Intervention: standard ABR measures (IT5 and I-V delay)
Number of subjects: 54
Study 12489899 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg in the first week, 200 mg in the second week)
Number of subjects: 15
Study 12489899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12489899 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 15
Study 10516393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) administered at 12 and 24 hours of age
Number of subjects: 40
Study 10516393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DEX treatment)
Number of subjects: 40
Study 10516393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DEX and control groups
Number of subjects: 40
Study 7793185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IM 6 hourly postoperatively
Number of subjects: 60
Study 7793185 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 7793185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60
Study 7793185 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac and Saline (both groups)
Number of subjects: 60
Study 1934440 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 50
Study 1934440 — intervention group
Group type: COMPARATOR
Intervention: Nonfiltered controls
Number of subjects: 50
Study 6366135 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard and 5-fluorouracil (PF) with tamoxifen (T)
Number of subjects: 1891
Study 6366135 — intervention group
Group type: COMPARATOR
Intervention: L-phenylalanine mustard and 5-fluorouracil (PF)
Number of subjects: 1891
Study 31037971 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper version of HM-PRO
Number of subjects: 193
Study 31037971 — intervention group
Group type: COMPARATOR
Intervention: Electronic version of HM-PRO
Number of subjects: 193
Study 31037971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both versions of HM-PRO
Number of subjects: 193
Study 30713751 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol only (Group 1)
Number of subjects: 112
Study 30713751 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose misoprostol + cervical Foley catheter (Group 2)
Number of subjects: 112
Study 30713751 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter only (Group 3)
Number of subjects: 112
Study 26466134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 13
Study 26466134 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PLACEBO)
Number of subjects: 13
Study 26466134 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 13
Study 26466134 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 13
Study 24148250 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacks provided under stressed conditions
Number of subjects: 248
Study 24148250 — intervention group
Group type: COMPARATOR
Intervention: Snacks provided under control conditions
Number of subjects: 248
Study 24148250 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration
Number of subjects: 248
Study 24148250 — intervention group
Group type: EXPERIMENTAL
Intervention: External stressor
Number of subjects: 248
Study 24148250 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 248
Study 24148250 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 248
Study 18272912 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and bevacizumab with cetuximab (arm B)
Number of subjects: 755
Study 18272912 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine, oxaliplatin, and bevacizumab without cetuximab (arm A)
Number of subjects: 755
Study 15361383 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg triamcinolone hexacetonide (0.25 ml)
Number of subjects: 40
Study 15361383 — intervention group
Group type: COMPARATOR
Intervention: Sterile 0.9% saline (0.25 ml)
Number of subjects: 40
Study 11129665 — intervention group
Group type: COMPARATOR
Intervention: 30 minutes' physiotherapy
Number of subjects: 114
Study 11129665 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes' physiotherapy
Number of subjects: 114
Study 9531231 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (initial dose 5 mg/d, increased to 10 mg/d at 24 months)
Number of subjects: 2027
Study 9531231 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 2027
Study 9531231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2027
Study 8232430 — intervention group
Group type: EXPERIMENTAL
Intervention: accelerated-dose tissue plasminogen activator (t-PA) with intravenous heparin
Number of subjects: 2431
Study 8232430 — intervention group
Group type: COMPARATOR
Intervention: streptokinase with subcutaneous heparin
Number of subjects: 2431
Study 8232430 — intervention group
Group type: COMPARATOR
Intervention: streptokinase with intravenous heparin
Number of subjects: 2431
Study 8232430 — intervention group
Group type: COMPARATOR
Intervention: combination of both activators plus intravenous heparin
Number of subjects: 2431
Study 8232430 — intervention group
Group type: COMPARATOR
Intervention: all treatment groups
Number of subjects: 2431
Study 8232430 — intervention group
Group type: COMPARATOR
Intervention: patients with normal coronary flow at 90 minutes
Number of subjects: 2431
Study 8232430 — intervention group
Group type: COMPARATOR
Intervention: patients with no flow at 90 minutes
Number of subjects: 2431
Study 3501221 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 50
Study 3501221 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 50
Study 30818931 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-enhanced group (40 μg at 0, 1, 2, 3 months; 60 μg at 4, 5, 6 months)
Number of subjects: 120
Study 30818931 — intervention group
Group type: COMPARATOR
Intervention: Rapid group (40 μg at 0, 1, 2, 3 months; 20 μg at 4, 5, 6 months)
Number of subjects: 120
Study 30818931 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful group (higher CTL and Th1 cell percentage increase)
Number of subjects: 120
Study 30818931 — intervention group
Group type: COMPARATOR
Intervention: Non-successful group (lower CTL and Th1 cell percentage increase)
Number of subjects: 120
Study 28575232 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 101
Study 28575232 — intervention group
Group type: COMPARATOR
Intervention: Statin nonusers
Number of subjects: 101
Study 28575232 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 101
Study 28575232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 26769956 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal bed rest in normobaric hypoxia (HBR)
Number of subjects: 11
Study 26769956 — intervention group
Group type: COMPARATOR
Intervention: Horizontal bed rest in normobaric normoxia (NBR)
Number of subjects: 11
Study 26769956 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal bed rest combined with daily moderate intensity exercise (HAMB)
Number of subjects: 11
Study 24120953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 24 weeks (n=16)
Number of subjects: 60
Study 24120953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (600 mg twice daily) for 24 weeks with peginterferon and ribavirin for 48 weeks (n=14)
Number of subjects: 60
Study 24120953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Number of subjects: 60
Study 24120953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Number of subjects: 60
Study 24120953 — intervention group
Group type: COMPARATOR
Intervention: Placebo with peginterferon and ribavirin for 48 weeks (n=14, control)
Number of subjects: 60
Study 22990394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (encouraged to increase daily steps to 10,000)
Number of subjects: 40
Study 22990394 — intervention group
Group type: COMPARATOR
Intervention: Control group (not asked to change daily steps)
Number of subjects: 40
Study 19460398 — intervention group
Group type: EXPERIMENTAL
Intervention: Interocularly matched target
Number of subjects: 0
Study 19460398 — intervention group
Group type: COMPARATOR
Intervention: Interocularly unmatched target
Number of subjects: 0
Study 17490918 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician‐delivered coronary heart disease risk evaluation and communication program
Number of subjects: 1500
Study 17490918 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1500
Study 15154941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30
Study 15154941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11524308 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 157
Study 11524308 — intervention group
Group type: COMPARATOR
Intervention: Acamprosate (1665‐1998 mg/day)
Number of subjects: 157
Study 10174217 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher assisted by older pupils
Number of subjects: 243
Study 10174217 — intervention group
Group type: COMPARATOR
Intervention: Teacher only
Number of subjects: 243
Study 10174217 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior knowledge of resuscitation techniques
Number of subjects: 243
Study 8178555 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 43
Study 8178555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43